Affordable Access

[Effectiveness of remission induction with high-dose cytarabine for relapsed or refractory pediatric acute leukemia].

Authors
  • Horikoshi, Yasuo
  • Kobayashi, Ryoji
  • Endo, Mikiya
  • Watanabe, Arata
  • Kikuta, Atsushi
  • Koike, Kazutoshi
  • Hanada, Ryoji
  • Hosoya, Ryota
  • Ohara, Akira
  • Ikuta, Koichiro
  • Goto, Hiroaki
  • Asami, Keiko
  • Sugita, Kanji
  • Horibe, Keizo
  • Tsurusawa, Masahito
  • Hori, Toshinari
  • Hara, Junichi
  • Nishimura, Shinichiro
  • Nagatoshi, Yoshihisa
  • Mugishima, Hideo
  • And 3 more
Type
Published Article
Journal
[Rinshō ketsueki] The Japanese journal of clinical hematology
Publication Date
Feb 01, 2010
Volume
51
Issue
2
Pages
104–113
Identifiers
PMID: 20379101
Source
Medline
License
Unknown

Abstract

We conducted a multicenter postmarketing study to investigate the efficacy and safety of reinduction therapy with a high-dose cytarabine-containing regimen for pediatric patients with relapsed or refractory acute leukemia. Seven of 13 patients (53.8%) with ALL achieved complete or partial remission, and only 1 of 6 patients (16.7%) with AML achieved partial remission. The frequent non-hematologic adverse events were gastrointestinal toxicities, such as vomiting, diarrhea and abdominal pain, as well as pyrexia and headache. Infection appeared in 9 of 20 (45%) patients. There were two death during reinduction therapy. One died of invasive bronchopulmonary aspergillosis, and the other died of intracranial hemorrhage and renal failure. These results indicated that a high-dose cytarabine regimen is effective as reinduction therapy in pediatric patients with relapsed ALL, and supportive care is essential to prevent or control treatment-related adverse events, such as infection.

Report this publication

Statistics

Seen <100 times